Q3 2025 Travere Therapeutics Inc Earnings Call Transcript

Oct 30, 2025 / 08:30PM GMT

Release Date Price: $29.65 (-1.10%)

Transcript 10-Q8-K

Key Points

Positve

Travere Therapeutics Inc (TVTX) reported strong commercial execution in IgA nephropathy with FILSPARI, achieving net product sales of approximately $91 million in the third quarter.
The FDA approved modifications to the FILSPARI REMS program, simplifying care by reducing liver monitoring frequency and removing embryo-fetal toxicity REMS.
FILSPARI's inclusion in the KDIGO guidelines as a first-line treatment for IgA nephropathy reinforces its position as a foundational therapy.
The company successfully manufactured the first commercial-scale batches of pegtibatinase, positioning it for a pivotal Phase 3 HARMONY study restart in 2026.
Travere Therapeutics Inc (TVTX) achieved a $40 million market access milestone from CSL Vifor, reflecting strong global partnerships and market expansion.

Negative

Despite strong performance, Travere Therapeutics Inc (TVTX) faces a competitive landscape with new product launches, although it has not significantly impacted their growth trajectory.
The company anticipates higher discounts in the fourth quarter, which may affect future revenue growth.
Operating expenses increased, particularly in SG&A, due to preparations for a potential FSGS launch and increased investment in FILSPARI's commercial efforts.
Travere Therapeutics Inc (TVTX) has not yet achieved full removal of the REMS program, with the FDA requiring exposure across 3,000 patients for two years.
The company is still in the process of scaling up manufacturing for pegtibatinase, which requires further characterization work and stock building for launch.

Operator

Good afternoon and welcome to the Travere Therapeutics third quarter 2025 Financial results conference call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice President Corporate Communications and Investor Relations. Please go ahead, Nivi.

Nivi Nehra

Travere Therapeutics Inc - Vice President, Head of Corporate Communications & Investor Relations

Thank you, operator. Good afternoon and welcome to Travere Therapeutics, the 3rd quarter 2025 Financial Results and Corporate Update call.

Thank you all for joining. Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric is joined in the prepared remarks by Dr. Julie Innes, our Chief Medical Officer; Peter Hecht, our Chief Commercial Officer; and Chris Klein, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.